KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Invested Capital (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Invested Capital for 16 consecutive years, with $2.2 billion as the latest value for Q4 2025.

  • Quarterly Invested Capital rose 17.21% to $2.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 billion through Dec 2025, up 17.21% year-over-year, with the annual reading at $2.2 billion for FY2025, 17.21% up from the prior year.
  • Invested Capital for Q4 2025 was $2.2 billion at Halozyme Therapeutics, up from $2.0 billion in the prior quarter.
  • The five-year high for Invested Capital was $2.2 billion in Q4 2025, with the low at $852.3 million in Q1 2021.
  • Average Invested Capital over 5 years is $1.6 billion, with a median of $1.7 billion recorded in 2022.
  • The sharpest move saw Invested Capital surged 551.59% in 2021, then dropped 5.54% in 2023.
  • Over 5 years, Invested Capital stood at $984.2 million in 2021, then soared by 70.28% to $1.7 billion in 2022, then fell by 5.54% to $1.6 billion in 2023, then increased by 18.1% to $1.9 billion in 2024, then increased by 17.21% to $2.2 billion in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $2.2 billion, $2.0 billion, and $1.8 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.